Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance
International Journal of Cancer · 15.02.2025 · 156 (4) · 689-699
DOI: 10.1002/ijc.35207 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 06.10.2024. Verfasst von Tong Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hemangioendothelioma, Sirolimus, Sarcoma, Kaposi, Kasabach-Merritt Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 135 Literaturangaben. Gefördert von: Key Project in the Science & Technology Program of Sichuan Province, '0 to 1' Project of Sichuan University, Med-X Center for Informatics Funding Project.
Abstract (Originalsprache)
Kaposiform hemangioendotheliomas (KHEs) are vascular tumors that are considered borderline or locally aggressive and may lead to lethal outcomes. Traditional therapies, such as surgery and embolization, may be insufficient or technically impossible for patients with KHE. Sirolimus (or rapamycin), a specific inhibitor of mechanistic target of rapamycin, has recently been demonstrated to be very useful in the treatment of KHEs. Here, we highlight recent substantial progress regarding the effects of sirolimus on KHEs and discuss the potential mechanisms of action of sirolimus in treating this disease. The prevention of platelet activation and inflammation, along with antiangiogenic effects, the inhibition of lymphangiogenesis, the attenuation of fibrosis, or a combination of all these effects, may be responsible for the therapeutic effects of sirolimus. In addition, the mechanism of sirolimus resistance in some KHE patients is discussed. Finally, we review the somatic mutations that have recently been identified in KEH lesions, and discuss the potential of novel therapeutic targets based on these further understandings of the cellular and molecular pathogenesis of KHE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
- Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
ORCID-Profile: Yi Ji
Förderung
- Key Project in the Science & Technology Program of Sichuan Province
- '0 to 1' Project of Sichuan University
- Med-X Center for Informatics Funding Project
- 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project of West China Hospital of Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Qiu, T., Xiang, S., Zhou, J., Yang, M., Lan, Y., Zhang, X., Gong, X., Zhang, Z., & Ji, Y. (2025). Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance. International Journal of Cancer, 156(4), 689-699. https://doi.org/10.1002/ijc.35207
Vancouver
Qiu T, Xiang S, Zhou J, Yang M, Lan Y, Zhang X, et al. Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance. International Journal of Cancer. 2025;156(4):689-699. doi:10.1002/ijc.35207
BibTeX
@article{Qiu2025,
author = {Qiu, Tong and Xiang, Shanshan and Zhou, Jiangyuan and Yang, Min and Lan, Yuru and Zhang, Xuepeng and Gong, Xue and Zhang, Zixin and Ji, Yi},
title = {Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {4},
pages = {689--699},
doi = {10.1002/ijc.35207}
}
EUVIMED